A detailed history of Profund Advisors LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 50,352 shares of NTLA stock, worth $703,417. This represents 0.04% of its overall portfolio holdings.

Number of Shares
50,352
Previous 38,947 29.28%
Holding current value
$703,417
Previous $871,000 18.71%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$19.72 - $27.36 $224,906 - $312,040
11,405 Added 29.28%
50,352 $1.03 Million
Q2 2024

Aug 13, 2024

SELL
$20.02 - $27.22 $187,247 - $254,588
-9,353 Reduced 19.36%
38,947 $871,000
Q1 2024

May 08, 2024

SELL
$23.82 - $32.8 $63,742 - $87,772
-2,676 Reduced 5.25%
48,300 $1.33 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $243,527 - $340,055
10,515 Added 25.99%
50,976 $1.55 Million
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $145,199 - $210,221
4,592 Added 12.8%
40,461 $1.28 Million
Q2 2023

Aug 10, 2023

SELL
$34.58 - $46.03 $9,302 - $12,382
-269 Reduced 0.74%
35,869 $1.46 Million
Q1 2023

May 11, 2023

BUY
$33.3 - $44.82 $819,279 - $1.1 Million
24,603 Added 213.29%
36,138 $1.35 Million
Q4 2022

Feb 02, 2023

BUY
$33.21 - $62.69 $48,420 - $91,402
1,458 Added 14.47%
11,535 $402,000
Q3 2022

Nov 04, 2022

BUY
$53.92 - $71.7 $22,215 - $29,540
412 Added 4.26%
10,077 $564,000
Q2 2022

Aug 01, 2022

SELL
$38.49 - $76.21 $39,298 - $77,810
-1,021 Reduced 9.55%
9,665 $500,000
Q1 2022

May 10, 2022

SELL
$58.27 - $118.99 $69,399 - $141,717
-1,191 Reduced 10.03%
10,686 $777,000
Q4 2021

Feb 08, 2022

SELL
$100.76 - $138.36 $123,027 - $168,937
-1,221 Reduced 9.32%
11,877 $1.4 Million
Q3 2021

Nov 12, 2021

BUY
$132.37 - $176.78 $1.49 Million - $1.98 Million
11,222 Added 598.19%
13,098 $1.76 Million
Q2 2021

Aug 12, 2021

BUY
$60.88 - $161.91 $114,210 - $303,743
1,876 New
1,876 $303,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.06B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.